Company / Capital Expenditures
Compass Therapeutics, Inc. Capital Expenditures History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$44.0K
FY2024
5-year range
$30.0K / $1.6M
FY2020-FY2024
Trend
+46.7%
vs FY2023
Sector context
#178 of 195
Health Care
What the data says
Among 195 Health Care companies, Compass Therapeutics, Inc. is in the bottom 9% for capital expenditures. Capital Expenditures returned to growth in FY2024 after 2 years of decline, reaching $44,000.
Based on SEC 10-K filings.
$44,000 in FY2024 with a 5-year CAGR of -37.6%.
Declined from $212,000 to $44,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -69.6%
- 5-Year CAGR
- -37.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 195This company $44.0K Sector average $116.9M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -37.6%, indicating a declining trend.
- In FY2024, capital expenditures increased 46.7% year-over-year.
- Ranks #178 out of 195 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $44.0K | +46.7% |
| FY2023 | $30.0K | -85.8% |
| FY2022 | $212.0K | -86.5% |
| FY2021 | $1.6M | +1379.2% |
| FY2020 | $106.0K | -77.3% |
| FY2019 | $466.0K | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026